An overview of peptide compounds used in central nervous system research, melanocortin receptor pharmacology, and neuropeptide signaling studies. This category covers compounds studied for their interactions with CNS receptor systems in laboratory and animal model contexts.
The central nervous system is richly modulated by neuropeptides, short amino acid sequences that act as signaling molecules in the brain and spinal cord. Unlike classical neurotransmitters, neuropeptides typically act through G protein-coupled receptors with high selectivity, making them valuable targets for pharmacological research aimed at understanding specific CNS circuits and functions.
Peptide tool compounds in cognitive and CNS research serve multiple purposes: as receptor agonists or antagonists in binding and functional assays, as probes for mapping receptor distribution and expression patterns, and as pharmacological comparators in studies of endogenous neuropeptide biology. Their peptide nature, which generally limits CNS penetration in intact animals, is itself a variable of interest in blood-brain barrier permeability research.
The melanocortin system in particular has attracted significant research interest due to the wide distribution of MC receptors across the brain, their involvement in energy homeostasis, autonomic function, and reward circuitry, and the availability of well-characterized peptide agonists and antagonists for receptor subtype-selective studies.
PT-141 research focuses on selective binding to melanocortin receptor subtypes 3 and 4, which are expressed in hypothalamic and limbic regions. Studies examine receptor binding kinetics, affinity constants, and downstream cAMP signaling cascades.
MC4R is a key regulator of hypothalamic energy balance circuits. Research uses melanocortin agonists to probe the arcuate nucleus–paraventricular nucleus axis and its role in integrating peripheral metabolic signals with CNS output.
Melanocortin receptor activation has documented effects on autonomic nervous system output. Research models examine cardiovascular parameters, sympathetic tone, and ANS-mediated physiological responses in rodent models treated with MC receptor agonists.
PT-141's cyclic peptide structure makes it a useful model compound for studying peptide blood-brain barrier penetration. Research examines the structural determinants of CNS access and pharmacokinetic modeling of cyclic versus linear peptide CNS distribution.
MC4R is expressed in limbic structures associated with reward and motivation. Research investigates melanocortin system contributions to mesolimbic dopamine pathway modulation and behavioral output in preclinical models.
The melanocortin system offers a relatively tractable entry point into CNS peptide pharmacology research. Five receptor subtypes with distinct tissue distributions, well-characterized endogenous ligands (α-MSH, β-MSH, γ-MSH, ACTH), and available selective synthetic agonists and antagonists create a research system with substantial comparative literature and established methodology.
PT-141 (Bremelanotide) has been used extensively as a pharmacological tool compound in melanocortin research because of its selective MC3R/MC4R activity profile and its cyclic peptide structure, which confers greater conformational stability than linear peptide analogs in assay conditions. This stability makes it particularly useful in receptor binding assays, cell-based functional screens, and in vivo pharmacology experiments requiring reproducible dose-response relationships.
The intersection of the melanocortin system with metabolic regulation is also of growing research interest. MC4R's documented role in energy balance, demonstrated by the obesity phenotype of MC4R knockout rodents, makes melanocortin agonist compounds useful tools for studying the CNS contribution to metabolic regulation, complementing the peripheral metabolic research conducted with GLP-1 class compounds.
Researchers studying neuropeptide GPCR pharmacology, hypothalamic circuit function, or CNS-peripheral crosstalk in metabolic biology will find PT-141 a well-characterized, literature-supported tool compound for these applications.
A cyclic heptapeptide melanocortin receptor agonist with selective activity at MC3R and MC4R. Derived from the linear peptide MT-II through lactam bridge cyclization, which enhances conformational stability and receptor selectivity. Used extensively in melanocortin pharmacology research, CNS receptor mapping, hypothalamic circuit studies, and comparative GPCR pharmacology. The cyclic structure makes it a useful model compound for peptide CNS penetration research.
Related: Tirzepatide CNS Research Profile →Additional CNS and neuropeptide research compounds are under evaluation for addition to this category. Contact us for current availability of specific research compounds not listed here.
Cyclic peptides present specific analytical challenges compared to linear peptides. The lactam bridge in PT-141 must be confirmed intact, as ring-opened (linear) forms may have substantially different receptor binding profiles. Standard HPLC purity analysis must be accompanied by mass spectrometry confirmation to distinguish cyclic from linear forms that may co-elute under some analytical conditions.
For CNS receptor pharmacology research, where precise dose-response relationships are critical for interpreting receptor affinity and functional potency data, compound purity directly affects the reliability of experimental results. Impurities at even low percentages can introduce off-target receptor interactions that confound the interpretation of melanocortin-specific effects.
All CNS research compounds supplied by Lone Star Peptide Co. are verified by independent third-party laboratories with specific attention to structural integrity confirmation alongside standard purity analysis. Certificates of Analysis are batch-specific and included with every order.
⚠ FOR RESEARCH USE ONLY, All compounds are intended exclusively for in vitro and laboratory research. Not approved by the FDA for human consumption or therapeutic use. Nothing on this page constitutes medical advice. Researchers are responsible for all applicable regulatory compliance prior to use.